The company
Avalo Therapeutics, Inc.
AVTX · Nasdaq
AVTX stood above a rising 150-day average in 32 of the last 52 weekly readings, and has been out of that trend for the last 6 weeks. It is 30.0% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 6
- Industry in uptrend
- 16% -15 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $16.8M
- Officials’ trades on record
- 0
- Institutions holding
- 125 (+31)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 32 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Christopher Ryan SullivanChief Financial Officer | sold | 12,394at $16.33 | 16 Sep 2026filed 18 Sep 2026 |
| Christopher Ryan SullivanChief Financial Officer | sold | 10,185at $17.62 | 10 Sep 2026filed 11 Sep 2026 |
| Mittie DoyleChief Medical Officer | sold | 679at $20.00 | 28 Aug 2026filed 1 Sep 2026 |
| Christopher Ryan SullivanChief Financial Officer | sold | 31,031at $20.05 | 18 Aug 2026filed 19 Aug 2026 |
| Christopher Ryan SullivanChief Financial Officer | sold | 37,945at $19.85 | 17 Aug 2026filed 19 Aug 2026 |
| Christopher Ryan SullivanChief Financial Officer | sold | 3,749at $19.94 | 17 Aug 2026filed 19 Aug 2026 |
| Mittie DoyleChief Medical Officer | sold | 1,000at $20.00 | 17 Aug 2026filed 19 Aug 2026 |
| Jennifer RileyChief Strategy Officer | sold | 2,655at $19.59 | 11 Aug 2026filed 12 Aug 2026 |
| Mittie DoyleChief Medical Officer | sold | 679at $20.00 | 10 Aug 2026filed 12 Aug 2026 |
| Mittie DoyleChief Medical Officer | sold | 1,000at $20.00 | 27 Jul 2026filed 29 Jul 2026 |
| Mittie DoyleChief Medical Officer | sold | 4,654at $20.00 | 30 Jun 2026filed 2 Jul 2026 |
| Mittie DoyleChief Medical Officer | sold | 1,450at $18.00 | 23 Jun 2026filed 25 Jun 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| FMR LLCadded · filed 13 Aug 2026 | 5,100,216$94.3M | +2,220,735+77.1% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 4,365,553$80.7M | +4,038,471+1234.7% |
| Deep Track Capital, LPnew · filed 14 Aug 2026 | 3,610,000$66.7M | +3,610,000 |
| Caligan Partners LPadded · filed 14 Aug 2026 | 3,163,866$58.5M | +1,528,843+93.5% |
| TCG Crossover Management, LLCadded · filed 14 Aug 2026 | 3,017,120$55.8M | +2,278,737+308.6% |
| Affinity Asset Advisors, LLCadded · filed 13 Aug 2026 | 2,900,000$53.6M | +1,559,160+116.3% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 2,889,287$53.4M | +2,817,633+3932.3% |
| FARALLON CAPITAL MANAGEMENT, L.L.C.added · filed 14 Aug 2026 | 2,498,000$46.2M | +1,582,000+172.7% |
| Point72 Asset Management, L.P.added · filed 14 Aug 2026 | 2,387,026$44.1M | +1,470,884+160.6% |
| Avoro Capital Advisors LLCadded · filed 14 Aug 2026 | 2,333,333$43.1M | +923,333+65.5% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.